Analysis of semaglutide from human plasma by LC-MS/MS

Written by Shimadzu Scientific Instruments
MS (LC–MS/MS, HRMS, IMS)

Semaglutide, developed as medication for the treatment of type 2 diabetes, became popular due to its effect on obesity. Recent studies indicate its potential in the treatment of neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease.

Analytically semaglutide is challenging, as its effective plasma concentration is low and needs to be detected against a high background noise level. Shimadzu has developed a highly sensitive, no carryover LC-MS/MS method to determine semaglutide in plasma using the Shimadzu Nexera X3 and the LCMS-8060NX. With an impressively low LOQ and a wide dynamic range, this method is ideal for reliable pharmacokinetic studies.

Learn more about the method in this Application Note from Shimadzu.


For more information visit:

This content has been provided by Shimadzu Europe. Check them out on LinkedIn!

In association with: